| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Palliative Care | 183 | 2024 | 2037 | 30.470 |
Why?
|
| Neoplasms | 227 | 2024 | 15193 | 14.530 |
Why?
|
| Terminal Care | 39 | 2024 | 447 | 10.460 |
Why?
|
| Delirium | 22 | 2024 | 207 | 8.720 |
Why?
|
| Dyspnea | 31 | 2024 | 416 | 7.280 |
Why?
|
| Sleep Apnea, Obstructive | 20 | 2022 | 228 | 6.820 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 29 | 2024 | 1021 | 6.000 |
Why?
|
| Analgesics, Opioid | 46 | 2023 | 1371 | 5.520 |
Why?
|
| Referral and Consultation | 35 | 2023 | 899 | 5.420 |
Why?
|
| Continuous Positive Airway Pressure | 13 | 2022 | 80 | 5.400 |
Why?
|
| Antipsychotic Agents | 12 | 2022 | 414 | 5.350 |
Why?
|
| Influenza, Human | 29 | 2024 | 925 | 4.660 |
Why?
|
| Coronavirus Infections | 23 | 2020 | 651 | 4.410 |
Why?
|
| Medical Oncology | 26 | 2023 | 1423 | 4.240 |
Why?
|
| Severe Acute Respiratory Syndrome | 25 | 2021 | 82 | 4.220 |
Why?
|
| Symptom Assessment | 14 | 2023 | 267 | 4.060 |
Why?
|
| Humans | 487 | 2024 | 261506 | 3.700 |
Why?
|
| Cancer Care Facilities | 18 | 2023 | 884 | 3.510 |
Why?
|
| Hospitalization | 44 | 2024 | 2083 | 3.440 |
Why?
|
| Hong Kong | 51 | 2024 | 71 | 3.300 |
Why?
|
| Respiratory Tract Infections | 12 | 2023 | 437 | 3.180 |
Why?
|
| Fentanyl | 9 | 2022 | 148 | 3.130 |
Why?
|
| Hospice and Palliative Care Nursing | 8 | 2023 | 56 | 3.120 |
Why?
|
| Ambulatory Care | 17 | 2023 | 554 | 3.090 |
Why?
|
| Opioid-Related Disorders | 15 | 2022 | 394 | 3.000 |
Why?
|
| Quality of Life | 50 | 2023 | 4532 | 2.940 |
Why?
|
| Quality of Health Care | 12 | 2020 | 621 | 2.890 |
Why?
|
| Haloperidol | 10 | 2021 | 64 | 2.880 |
Why?
|
| Pandemics | 29 | 2023 | 1559 | 2.650 |
Why?
|
| Male | 273 | 2024 | 123000 | 2.590 |
Why?
|
| Delivery of Health Care, Integrated | 7 | 2020 | 164 | 2.510 |
Why?
|
| Severity of Illness Index | 37 | 2022 | 4320 | 2.460 |
Why?
|
| Aged | 195 | 2024 | 70117 | 2.440 |
Why?
|
| Middle Aged | 218 | 2024 | 86204 | 2.440 |
Why?
|
| Prospective Studies | 80 | 2024 | 12873 | 2.440 |
Why?
|
| Disease Outbreaks | 14 | 2022 | 415 | 2.360 |
Why?
|
| Patient Care Team | 16 | 2020 | 795 | 2.310 |
Why?
|
| Female | 261 | 2024 | 141928 | 2.310 |
Why?
|
| Surveys and Questionnaires | 44 | 2024 | 5687 | 2.300 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 11 | 2023 | 242 | 2.260 |
Why?
|
| Asthma | 10 | 2022 | 871 | 2.250 |
Why?
|
| Respiratory Insufficiency | 6 | 2023 | 330 | 2.240 |
Why?
|
| Adult | 177 | 2023 | 77950 | 2.190 |
Why?
|
| Hospice Care | 10 | 2022 | 156 | 2.180 |
Why?
|
| Pneumonia, Viral | 16 | 2020 | 715 | 2.150 |
Why?
|
| Masks | 6 | 2020 | 57 | 2.130 |
Why?
|
| Cancer Pain | 15 | 2023 | 312 | 2.100 |
Why?
|
| Outpatients | 23 | 2023 | 462 | 2.090 |
Why?
|
| Aged, 80 and over | 113 | 2024 | 29902 | 2.070 |
Why?
|
| Exhalation | 8 | 2019 | 60 | 2.040 |
Why?
|
| Pain | 25 | 2023 | 1658 | 2.010 |
Why?
|
| Death | 7 | 2023 | 119 | 2.000 |
Why?
|
| Polysomnography | 11 | 2021 | 155 | 1.960 |
Why?
|
| Caregivers | 15 | 2021 | 677 | 1.950 |
Why?
|
| Adrenal Cortex Hormones | 10 | 2024 | 544 | 1.950 |
Why?
|
| Terminally Ill | 6 | 2021 | 91 | 1.930 |
Why?
|
| Hospices | 4 | 2023 | 51 | 1.930 |
Why?
|
| Patient Readmission | 8 | 2023 | 548 | 1.910 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 4 | 2018 | 28 | 1.900 |
Why?
|
| Oxygen Inhalation Therapy | 8 | 2023 | 119 | 1.880 |
Why?
|
| Prognosis | 51 | 2023 | 21713 | 1.800 |
Why?
|
| Double-Blind Method | 20 | 2023 | 2588 | 1.790 |
Why?
|
| Decision Making | 13 | 2023 | 1287 | 1.710 |
Why?
|
| Exercise | 7 | 2021 | 1183 | 1.680 |
Why?
|
| Patients | 7 | 2015 | 245 | 1.670 |
Why?
|
| Dexamethasone | 7 | 2023 | 1450 | 1.660 |
Why?
|
| Longitudinal Studies | 24 | 2021 | 1945 | 1.660 |
Why?
|
| Cachexia | 10 | 2017 | 161 | 1.650 |
Why?
|
| Pneumonia, Bacterial | 5 | 2015 | 130 | 1.620 |
Why?
|
| Betacoronavirus | 12 | 2020 | 527 | 1.600 |
Why?
|
| Benzodiazepines | 3 | 2022 | 170 | 1.570 |
Why?
|
| Tertiary Care Centers | 8 | 2019 | 403 | 1.560 |
Why?
|
| Physical Examination | 5 | 2015 | 299 | 1.540 |
Why?
|
| Psychomotor Agitation | 3 | 2021 | 78 | 1.520 |
Why?
|
| Forced Expiratory Volume | 16 | 2019 | 314 | 1.490 |
Why?
|
| Hematologic Neoplasms | 6 | 2022 | 1870 | 1.480 |
Why?
|
| Cannula | 3 | 2020 | 35 | 1.470 |
Why?
|
| Spirituality | 9 | 2021 | 129 | 1.450 |
Why?
|
| Specialization | 3 | 2015 | 130 | 1.450 |
Why?
|
| Walking | 4 | 2019 | 277 | 1.430 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2018 | 1303 | 1.410 |
Why?
|
| Critical Care | 11 | 2019 | 770 | 1.400 |
Why?
|
| Coronavirus | 3 | 2014 | 40 | 1.390 |
Why?
|
| Survival Analysis | 27 | 2023 | 9180 | 1.380 |
Why?
|
| Electric Impedance | 4 | 2019 | 100 | 1.370 |
Why?
|
| Fatigue | 17 | 2021 | 1239 | 1.350 |
Why?
|
| Patient Compliance | 7 | 2015 | 667 | 1.340 |
Why?
|
| Cross-Over Studies | 5 | 2020 | 460 | 1.320 |
Why?
|
| Cross Infection | 6 | 2018 | 544 | 1.320 |
Why?
|
| China | 16 | 2020 | 606 | 1.310 |
Why?
|
| Attitude of Health Personnel | 8 | 2021 | 918 | 1.280 |
Why?
|
| Antiemetics | 5 | 2021 | 125 | 1.280 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2023 | 2594 | 1.270 |
Why?
|
| Palliative Medicine | 4 | 2021 | 23 | 1.260 |
Why?
|
| Delivery of Health Care | 7 | 2024 | 860 | 1.250 |
Why?
|
| Antiviral Agents | 18 | 2024 | 1230 | 1.210 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2021 | 211 | 1.180 |
Why?
|
| Minimal Clinically Important Difference | 2 | 2018 | 19 | 1.180 |
Why?
|
| Communicable Diseases, Emerging | 6 | 2020 | 87 | 1.180 |
Why?
|
| Patient Preference | 6 | 2023 | 218 | 1.170 |
Why?
|
| Respiratory Tract Diseases | 3 | 2022 | 111 | 1.170 |
Why?
|
| Air Pollution | 2 | 2022 | 87 | 1.160 |
Why?
|
| Pain Management | 13 | 2021 | 668 | 1.140 |
Why?
|
| Hand Strength | 3 | 2017 | 65 | 1.130 |
Why?
|
| Length of Stay | 11 | 2022 | 1900 | 1.120 |
Why?
|
| Young Adult | 53 | 2021 | 21445 | 1.120 |
Why?
|
| Communication | 10 | 2023 | 876 | 1.120 |
Why?
|
| Communicable Disease Control | 3 | 2023 | 175 | 1.110 |
Why?
|
| Seasons | 8 | 2023 | 340 | 1.100 |
Why?
|
| Models, Statistical | 4 | 2022 | 1171 | 1.100 |
Why?
|
| Dementia | 2 | 2021 | 453 | 1.100 |
Why?
|
| Air Pollutants | 2 | 2022 | 139 | 1.100 |
Why?
|
| Lorazepam | 4 | 2021 | 40 | 1.090 |
Why?
|
| Disease Progression | 14 | 2023 | 6682 | 1.080 |
Why?
|
| Airway Obstruction | 2 | 2021 | 261 | 1.080 |
Why?
|
| Respiratory Function Tests | 9 | 2023 | 318 | 1.080 |
Why?
|
| Lung | 10 | 2017 | 3151 | 1.080 |
Why?
|
| Pilot Projects | 17 | 2023 | 2803 | 1.070 |
Why?
|
| Oncologists | 4 | 2023 | 134 | 1.070 |
Why?
|
| Publishing | 3 | 2013 | 220 | 1.070 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2017 | 461 | 1.060 |
Why?
|
| Systems Integration | 2 | 2015 | 76 | 1.060 |
Why?
|
| Models, Organizational | 4 | 2020 | 76 | 1.050 |
Why?
|
| Goals | 5 | 2023 | 185 | 1.040 |
Why?
|
| Inpatients | 12 | 2023 | 678 | 1.040 |
Why?
|
| Retrospective Studies | 70 | 2023 | 37905 | 1.030 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2021 | 82 | 1.020 |
Why?
|
| Expert Testimony | 2 | 2015 | 90 | 1.010 |
Why?
|
| Physicians | 6 | 2023 | 882 | 1.000 |
Why?
|
| Bibliometrics | 3 | 2021 | 71 | 1.000 |
Why?
|
| Models, Theoretical | 5 | 2015 | 785 | 0.990 |
Why?
|
| Buprenorphine | 4 | 2018 | 96 | 0.980 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2016 | 79 | 0.980 |
Why?
|
| Drug Resistance, Bacterial | 4 | 2014 | 418 | 0.960 |
Why?
|
| Comorbidity | 18 | 2021 | 2352 | 0.960 |
Why?
|
| Cohort Studies | 28 | 2023 | 9244 | 0.950 |
Why?
|
| Bacteria | 4 | 2021 | 611 | 0.930 |
Why?
|
| Positive-Pressure Respiration | 5 | 2008 | 116 | 0.930 |
Why?
|
| Terminology as Topic | 4 | 2014 | 414 | 0.910 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 7 | 2020 | 58 | 0.910 |
Why?
|
| Treatment Outcome | 44 | 2022 | 32848 | 0.890 |
Why?
|
| Stress, Psychological | 10 | 2017 | 1000 | 0.870 |
Why?
|
| Point-of-Care Systems | 2 | 2023 | 196 | 0.870 |
Why?
|
| Awareness | 2 | 2021 | 126 | 0.870 |
Why?
|
| Practice Guidelines as Topic | 6 | 2021 | 2403 | 0.870 |
Why?
|
| Body Composition | 5 | 2019 | 595 | 0.860 |
Why?
|
| Respiration Disorders | 1 | 2022 | 45 | 0.850 |
Why?
|
| Morphine | 12 | 2023 | 308 | 0.850 |
Why?
|
| Spirometry | 9 | 2023 | 143 | 0.840 |
Why?
|
| Pneumonia | 7 | 2022 | 751 | 0.840 |
Why?
|
| Quality Indicators, Health Care | 2 | 2015 | 348 | 0.830 |
Why?
|
| Professional-Family Relations | 2 | 2021 | 134 | 0.830 |
Why?
|
| Physician-Patient Relations | 7 | 2023 | 792 | 0.830 |
Why?
|
| Health Services Accessibility | 4 | 2017 | 761 | 0.820 |
Why?
|
| Exercise Tolerance | 3 | 2014 | 107 | 0.820 |
Why?
|
| Disclosure | 2 | 2021 | 181 | 0.820 |
Why?
|
| Influenza A virus | 5 | 2023 | 270 | 0.810 |
Why?
|
| Time Factors | 24 | 2021 | 12926 | 0.800 |
Why?
|
| Nutritional Status | 3 | 2022 | 337 | 0.800 |
Why?
|
| Acute Disease | 8 | 2015 | 2422 | 0.800 |
Why?
|
| ROC Curve | 10 | 2019 | 1183 | 0.790 |
Why?
|
| Forecasting | 3 | 2020 | 694 | 0.790 |
Why?
|
| Intermittent Positive-Pressure Ventilation | 1 | 2021 | 13 | 0.790 |
Why?
|
| Home Nursing | 2 | 2018 | 25 | 0.790 |
Why?
|
| Health Impact Assessment | 1 | 2021 | 3 | 0.790 |
Why?
|
| Heart Failure | 5 | 2023 | 2516 | 0.790 |
Why?
|
| Anti-Bacterial Agents | 8 | 2023 | 2992 | 0.780 |
Why?
|
| Religion and Medicine | 3 | 2018 | 50 | 0.780 |
Why?
|
| Research Design | 7 | 2016 | 1544 | 0.780 |
Why?
|
| Prevalence | 18 | 2019 | 3260 | 0.770 |
Why?
|
| Adaptation, Psychological | 8 | 2024 | 764 | 0.760 |
Why?
|
| Eosinophils | 2 | 2019 | 162 | 0.740 |
Why?
|
| Monitoring, Physiologic | 2 | 2017 | 502 | 0.740 |
Why?
|
| Edema | 2 | 2019 | 267 | 0.730 |
Why?
|
| Quality Improvement | 3 | 2017 | 851 | 0.730 |
Why?
|
| Acupuncture Points | 2 | 2010 | 18 | 0.730 |
Why?
|
| Oxygen | 2 | 2023 | 754 | 0.730 |
Why?
|
| Oseltamivir | 6 | 2024 | 33 | 0.720 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 2 | 2010 | 26 | 0.720 |
Why?
|
| Mental Competency | 1 | 2020 | 62 | 0.720 |
Why?
|
| Public Opinion | 1 | 2020 | 83 | 0.710 |
Why?
|
| Bronchodilator Agents | 4 | 2024 | 219 | 0.710 |
Why?
|
| Home Care Services | 3 | 2017 | 92 | 0.710 |
Why?
|
| Patient Dropouts | 3 | 2017 | 88 | 0.710 |
Why?
|
| Symptom Flare Up | 1 | 2019 | 22 | 0.710 |
Why?
|
| Family | 2 | 2021 | 736 | 0.700 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 6 | 2023 | 152 | 0.700 |
Why?
|
| Anti-Anxiety Agents | 2 | 2017 | 90 | 0.700 |
Why?
|
| Rhinovirus | 1 | 2019 | 94 | 0.700 |
Why?
|
| Benchmarking | 2 | 2021 | 273 | 0.700 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 199 | 0.690 |
Why?
|
| Metronidazole | 1 | 2020 | 149 | 0.690 |
Why?
|
| Drug Therapy, Combination | 10 | 2024 | 2315 | 0.690 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2019 | 68 | 0.690 |
Why?
|
| Health Status Indicators | 2 | 2019 | 224 | 0.690 |
Why?
|
| Nasopharynx | 6 | 2020 | 119 | 0.680 |
Why?
|
| Sleep Stages | 2 | 2016 | 78 | 0.680 |
Why?
|
| Bacterial Infections | 4 | 2014 | 479 | 0.680 |
Why?
|
| Sputum | 5 | 2020 | 141 | 0.680 |
Why?
|
| Administration, Sublingual | 2 | 2019 | 25 | 0.670 |
Why?
|
| Advance Care Planning | 1 | 2020 | 86 | 0.670 |
Why?
|
| Weight Loss | 5 | 2022 | 627 | 0.660 |
Why?
|
| Risk Factors | 29 | 2022 | 17523 | 0.660 |
Why?
|
| Antibodies, Viral | 7 | 2023 | 1320 | 0.660 |
Why?
|
| Depression | 12 | 2023 | 1715 | 0.660 |
Why?
|
| Health Status | 3 | 2011 | 590 | 0.650 |
Why?
|
| Otolaryngology | 1 | 2020 | 129 | 0.650 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2019 | 92 | 0.650 |
Why?
|
| Multivariate Analysis | 17 | 2019 | 4298 | 0.650 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 1586 | 0.650 |
Why?
|
| Tranquilizing Agents | 1 | 2018 | 6 | 0.650 |
Why?
|
| Asia | 4 | 2022 | 142 | 0.640 |
Why?
|
| Cross-Sectional Studies | 17 | 2024 | 4314 | 0.640 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2021 | 1209 | 0.630 |
Why?
|
| Vital Capacity | 4 | 2011 | 131 | 0.630 |
Why?
|
| Uncertainty | 1 | 2019 | 320 | 0.620 |
Why?
|
| Narcotics | 1 | 2018 | 123 | 0.620 |
Why?
|
| Attitude to Death | 4 | 2020 | 100 | 0.610 |
Why?
|
| Family Characteristics | 1 | 2018 | 102 | 0.610 |
Why?
|
| Economics, Hospital | 1 | 2017 | 11 | 0.600 |
Why?
|
| Opiate Substitution Treatment | 4 | 2018 | 30 | 0.600 |
Why?
|
| Global Health | 5 | 2020 | 657 | 0.600 |
Why?
|
| United States | 15 | 2023 | 15433 | 0.600 |
Why?
|
| Electrodiagnosis | 1 | 2016 | 19 | 0.600 |
Why?
|
| Macrolides | 1 | 2017 | 62 | 0.590 |
Why?
|
| Off-Label Use | 1 | 2017 | 46 | 0.590 |
Why?
|
| Adolescent | 36 | 2023 | 31252 | 0.590 |
Why?
|
| Cytokines | 9 | 2021 | 2809 | 0.590 |
Why?
|
| Nausea | 7 | 2021 | 525 | 0.590 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 94 | 0.590 |
Why?
|
| Azithromycin | 1 | 2017 | 78 | 0.580 |
Why?
|
| Patient Acuity | 2 | 2020 | 72 | 0.580 |
Why?
|
| Pectins | 1 | 2016 | 10 | 0.580 |
Why?
|
| Reproducibility of Results | 11 | 2023 | 6009 | 0.570 |
Why?
|
| Consensus | 7 | 2022 | 978 | 0.560 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 343 | 0.560 |
Why?
|
| Neuraminidase | 2 | 2022 | 69 | 0.560 |
Why?
|
| Conscious Sedation | 1 | 2017 | 104 | 0.560 |
Why?
|
| Intra-Abdominal Fat | 1 | 2016 | 95 | 0.560 |
Why?
|
| Insulin Resistance | 1 | 2022 | 731 | 0.560 |
Why?
|
| Positive-Pressure Respiration, Intrinsic | 1 | 2015 | 3 | 0.560 |
Why?
|
| Infection Control | 3 | 2022 | 270 | 0.550 |
Why?
|
| Adiponectin | 1 | 2016 | 163 | 0.550 |
Why?
|
| Brazil | 6 | 2019 | 165 | 0.540 |
Why?
|
| Hydrogen | 1 | 2015 | 58 | 0.540 |
Why?
|
| Undocumented Immigrants | 1 | 2015 | 17 | 0.540 |
Why?
|
| Oxygen Consumption | 4 | 2011 | 401 | 0.540 |
Why?
|
| Critical Pathways | 2 | 2018 | 149 | 0.540 |
Why?
|
| Interdisciplinary Communication | 3 | 2018 | 280 | 0.540 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2022 | 907 | 0.540 |
Why?
|
| Urban Health | 1 | 2015 | 75 | 0.540 |
Why?
|
| Adenovirus Infections, Human | 1 | 2015 | 56 | 0.530 |
Why?
|
| Virus Diseases | 3 | 2014 | 398 | 0.530 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 421 | 0.530 |
Why?
|
| Cross-Linking Reagents | 1 | 2015 | 153 | 0.530 |
Why?
|
| Lysosomes | 3 | 2021 | 347 | 0.520 |
Why?
|
| Republic of Korea | 7 | 2023 | 70 | 0.520 |
Why?
|
| Superinfection | 1 | 2015 | 12 | 0.520 |
Why?
|
| Paramyxoviridae Infections | 1 | 2015 | 86 | 0.520 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 3 | 2018 | 36 | 0.520 |
Why?
|
| Primary Health Care | 3 | 2018 | 787 | 0.510 |
Why?
|
| Patient Selection | 3 | 2019 | 2055 | 0.510 |
Why?
|
| Thoracic Neoplasms | 1 | 2018 | 337 | 0.510 |
Why?
|
| Internet | 1 | 2019 | 706 | 0.510 |
Why?
|
| Bronchiectasis | 2 | 2014 | 26 | 0.510 |
Why?
|
| Walk Test | 4 | 2019 | 43 | 0.510 |
Why?
|
| Delphi Technique | 5 | 2022 | 210 | 0.510 |
Why?
|
| Texas | 18 | 2017 | 6311 | 0.500 |
Why?
|
| Psychometrics | 6 | 2023 | 937 | 0.500 |
Why?
|
| Managed Care Programs | 1 | 2014 | 74 | 0.500 |
Why?
|
| Age Factors | 14 | 2021 | 5377 | 0.500 |
Why?
|
| C-Reactive Protein | 6 | 2022 | 527 | 0.500 |
Why?
|
| Jordan | 4 | 2023 | 24 | 0.500 |
Why?
|
| Administration, Rectal | 1 | 2014 | 13 | 0.500 |
Why?
|
| Breath Tests | 5 | 2012 | 177 | 0.500 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2015 | 427 | 0.500 |
Why?
|
| Death, Sudden | 1 | 2014 | 59 | 0.500 |
Why?
|
| Withholding Treatment | 2 | 2018 | 161 | 0.490 |
Why?
|
| Inhalation | 1 | 2014 | 42 | 0.490 |
Why?
|
| Medication Therapy Management | 1 | 2014 | 36 | 0.490 |
Why?
|
| Vital Signs | 1 | 2014 | 25 | 0.490 |
Why?
|
| Drug Resistance, Viral | 1 | 2014 | 71 | 0.490 |
Why?
|
| Polymers | 1 | 2015 | 223 | 0.490 |
Why?
|
| Drug Resistance, Fungal | 1 | 2014 | 92 | 0.480 |
Why?
|
| Physical Exertion | 3 | 2020 | 113 | 0.480 |
Why?
|
| Lactic Acid | 1 | 2015 | 305 | 0.480 |
Why?
|
| Cough | 2 | 2012 | 116 | 0.470 |
Why?
|
| Oncology Service, Hospital | 1 | 2013 | 48 | 0.470 |
Why?
|
| Ambulatory Care Facilities | 4 | 2022 | 289 | 0.470 |
Why?
|
| Spouse Abuse | 1 | 2013 | 21 | 0.460 |
Why?
|
| Bronchitis, Chronic | 2 | 2011 | 30 | 0.460 |
Why?
|
| Vomiting | 5 | 2021 | 354 | 0.460 |
Why?
|
| Case Management | 1 | 2013 | 35 | 0.450 |
Why?
|
| Guideline Adherence | 1 | 2017 | 636 | 0.450 |
Why?
|
| Intensive Care Units | 8 | 2022 | 717 | 0.450 |
Why?
|
| Viral Load | 5 | 2017 | 493 | 0.440 |
Why?
|
| Genome, Viral | 1 | 2013 | 155 | 0.440 |
Why?
|
| Mental Disorders | 2 | 2018 | 862 | 0.440 |
Why?
|
| Obesity | 4 | 2022 | 2884 | 0.440 |
Why?
|
| Hypnotics and Sedatives | 5 | 2022 | 218 | 0.430 |
Why?
|
| Electroencephalography | 1 | 2017 | 898 | 0.430 |
Why?
|
| Respiratory System | 2 | 2013 | 125 | 0.430 |
Why?
|
| Mortality | 1 | 2014 | 343 | 0.430 |
Why?
|
| Follow-Up Studies | 19 | 2022 | 14889 | 0.430 |
Why?
|
| Patient Education as Topic | 5 | 2019 | 748 | 0.430 |
Why?
|
| Comprehensive Health Care | 1 | 2012 | 49 | 0.420 |
Why?
|
| Dust | 1 | 2012 | 39 | 0.420 |
Why?
|
| Cannabis | 2 | 2023 | 65 | 0.420 |
Why?
|
| Patient Care Planning | 5 | 2023 | 297 | 0.410 |
Why?
|
| Life Style | 1 | 2015 | 612 | 0.410 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 862 | 0.410 |
Why?
|
| Ventilation | 1 | 2011 | 20 | 0.410 |
Why?
|
| Research Support as Topic | 1 | 2012 | 122 | 0.410 |
Why?
|
| Protein Sorting Signals | 3 | 2002 | 44 | 0.410 |
Why?
|
| Environment, Controlled | 1 | 2011 | 21 | 0.410 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2013 | 170 | 0.410 |
Why?
|
| Conflict of Interest | 1 | 2012 | 98 | 0.400 |
Why?
|
| Bibliography of Medicine | 1 | 2011 | 3 | 0.400 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2021 | 709 | 0.400 |
Why?
|
| Karnofsky Performance Status | 3 | 2016 | 175 | 0.400 |
Why?
|
| Carotid Arteries | 2 | 2012 | 240 | 0.400 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 245 | 0.400 |
Why?
|
| Hemolysin Proteins | 2 | 2002 | 27 | 0.400 |
Why?
|
| Social Support | 1 | 2014 | 560 | 0.390 |
Why?
|
| Antineoplastic Agents | 7 | 2021 | 14289 | 0.390 |
Why?
|
| Mass Screening | 7 | 2022 | 1509 | 0.390 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2010 | 9 | 0.390 |
Why?
|
| Pulmonary Ventilation | 2 | 2010 | 45 | 0.390 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 509 | 0.390 |
Why?
|
| Body Mass Index | 5 | 2020 | 2203 | 0.380 |
Why?
|
| Mycoses | 1 | 2014 | 386 | 0.380 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2010 | 26 | 0.380 |
Why?
|
| Biomarkers | 9 | 2023 | 5047 | 0.380 |
Why?
|
| beta-Endorphin | 1 | 2010 | 42 | 0.380 |
Why?
|
| Receptors, LDL | 1 | 2011 | 109 | 0.380 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 144 | 0.370 |
Why?
|
| Diagnostic Equipment | 1 | 2010 | 1 | 0.370 |
Why?
|
| Research | 1 | 2013 | 415 | 0.370 |
Why?
|
| Clinical Competence | 3 | 2019 | 1270 | 0.370 |
Why?
|
| Interleukin-8 | 2 | 2010 | 519 | 0.370 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 2 | 2024 | 106 | 0.360 |
Why?
|
| Chlamydophila Infections | 1 | 2009 | 4 | 0.360 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2009 | 12 | 0.360 |
Why?
|
| Sensitivity and Specificity | 10 | 2015 | 4971 | 0.360 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2009 | 13 | 0.360 |
Why?
|
| Incidence | 7 | 2019 | 5673 | 0.360 |
Why?
|
| Deglutition Disorders | 1 | 2014 | 447 | 0.360 |
Why?
|
| Community-Acquired Infections | 2 | 2009 | 285 | 0.360 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2009 | 13 | 0.360 |
Why?
|
| Encephalitis, Viral | 1 | 2010 | 30 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2019 | 4938 | 0.350 |
Why?
|
| Nitric Oxide | 2 | 2012 | 644 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 4 | 2015 | 5061 | 0.350 |
Why?
|
| Leukotriene B4 | 1 | 2009 | 20 | 0.350 |
Why?
|
| Precision Medicine | 3 | 2014 | 1154 | 0.350 |
Why?
|
| Lung Volume Measurements | 1 | 2009 | 88 | 0.350 |
Why?
|
| Dysbiosis | 2 | 2021 | 134 | 0.350 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 834 | 0.340 |
Why?
|
| Neoplasm Staging | 7 | 2019 | 13658 | 0.340 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 3 | 2017 | 68 | 0.340 |
Why?
|
| Patient Discharge | 4 | 2013 | 661 | 0.340 |
Why?
|
| Age Distribution | 4 | 2015 | 698 | 0.340 |
Why?
|
| Drug Resistance, Microbial | 2 | 2023 | 218 | 0.340 |
Why?
|
| Singapore | 4 | 2020 | 31 | 0.340 |
Why?
|
| Hepatocytes | 1 | 2011 | 351 | 0.330 |
Why?
|
| Statistics, Nonparametric | 7 | 2017 | 980 | 0.330 |
Why?
|
| Cell Membrane | 2 | 2018 | 850 | 0.330 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2019 | 332 | 0.330 |
Why?
|
| Enzyme Inhibitors | 2 | 2022 | 1879 | 0.330 |
Why?
|
| Chemokines, CXC | 2 | 2005 | 117 | 0.330 |
Why?
|
| Substance Abuse Detection | 2 | 2020 | 64 | 0.330 |
Why?
|
| Camelus | 3 | 2018 | 7 | 0.320 |
Why?
|
| Survivors | 3 | 2017 | 1031 | 0.320 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 585 | 0.320 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 3 | 2017 | 25 | 0.320 |
Why?
|
| Aerosols | 4 | 2020 | 158 | 0.320 |
Why?
|
| Pain Measurement | 7 | 2021 | 953 | 0.310 |
Why?
|
| Liver | 4 | 2020 | 2961 | 0.310 |
Why?
|
| Anorexia | 3 | 2021 | 143 | 0.310 |
Why?
|
| Physical Fitness | 2 | 2005 | 122 | 0.310 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 276 | 0.310 |
Why?
|
| Vaccines | 2 | 2024 | 389 | 0.310 |
Why?
|
| RNA Viruses | 1 | 2007 | 43 | 0.300 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 604 | 0.300 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2023 | 134 | 0.300 |
Why?
|
| Noninvasive Ventilation | 2 | 2020 | 37 | 0.300 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 1011 | 0.300 |
Why?
|
| Self Report | 4 | 2024 | 756 | 0.300 |
Why?
|
| Motor Vehicles | 1 | 2006 | 8 | 0.300 |
Why?
|
| Analgesics | 1 | 2010 | 390 | 0.290 |
Why?
|
| Patient Simulation | 3 | 2012 | 40 | 0.290 |
Why?
|
| Substance-Related Disorders | 3 | 2024 | 524 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 1538 | 0.290 |
Why?
|
| Cost of Illness | 4 | 2017 | 498 | 0.290 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 259 | 0.290 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 849 | 0.290 |
Why?
|
| Automobile Driving | 1 | 2006 | 29 | 0.290 |
Why?
|
| Exercise Therapy | 2 | 2012 | 288 | 0.290 |
Why?
|
| Poultry | 2 | 2017 | 10 | 0.290 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 423 | 0.290 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 7789 | 0.290 |
Why?
|
| Periodicals as Topic | 1 | 2011 | 338 | 0.290 |
Why?
|
| Resuscitation Orders | 3 | 2013 | 68 | 0.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 5319 | 0.280 |
Why?
|
| Serum Albumin | 3 | 2017 | 257 | 0.280 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 799 | 0.280 |
Why?
|
| Influenza in Birds | 2 | 2017 | 26 | 0.280 |
Why?
|
| Prostaglandins A | 1 | 2005 | 2 | 0.280 |
Why?
|
| Case-Control Studies | 10 | 2016 | 6100 | 0.270 |
Why?
|
| Hospital Mortality | 3 | 2022 | 1274 | 0.270 |
Why?
|
| Chiroptera | 2 | 2016 | 45 | 0.260 |
Why?
|
| ATP Binding Cassette Transporter 1 | 2 | 2018 | 29 | 0.260 |
Why?
|
| Apolipoproteins E | 2 | 2008 | 221 | 0.260 |
Why?
|
| Patient Satisfaction | 6 | 2017 | 915 | 0.260 |
Why?
|
| Anxiety | 6 | 2023 | 1179 | 0.260 |
Why?
|
| Ritonavir | 2 | 2023 | 67 | 0.260 |
Why?
|
| Logistic Models | 8 | 2014 | 3441 | 0.260 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 2 | 2017 | 24 | 0.260 |
Why?
|
| Sex Distribution | 3 | 2015 | 495 | 0.260 |
Why?
|
| Leukocyte Count | 2 | 2019 | 684 | 0.260 |
Why?
|
| CDC2 Protein Kinase | 1 | 2005 | 176 | 0.260 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 3719 | 0.260 |
Why?
|
| South America | 2 | 2022 | 52 | 0.260 |
Why?
|
| Nomograms | 2 | 2021 | 313 | 0.250 |
Why?
|
| Chemokine CCL2 | 1 | 2005 | 203 | 0.250 |
Why?
|
| Metagenomics | 2 | 2022 | 115 | 0.250 |
Why?
|
| Escherichia coli | 2 | 2002 | 1203 | 0.250 |
Why?
|
| Appetite | 2 | 2016 | 73 | 0.250 |
Why?
|
| Exercise Test | 3 | 2013 | 312 | 0.250 |
Why?
|
| Survival Rate | 6 | 2019 | 12221 | 0.240 |
Why?
|
| Hiccup | 2 | 2015 | 17 | 0.240 |
Why?
|
| Guanidines | 2 | 2015 | 60 | 0.240 |
Why?
|
| Models, Biological | 3 | 2010 | 3254 | 0.240 |
Why?
|
| Cyclopentanes | 2 | 2015 | 40 | 0.240 |
Why?
|
| Existentialism | 2 | 2021 | 9 | 0.240 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2014 | 1664 | 0.230 |
Why?
|
| Platelet Activation | 1 | 2004 | 116 | 0.230 |
Why?
|
| Body Dysmorphic Disorders | 2 | 2014 | 31 | 0.230 |
Why?
|
| Aspartate Aminotransferases | 2 | 2021 | 153 | 0.230 |
Why?
|
| Administration, Intranasal | 2 | 2016 | 190 | 0.230 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 2195 | 0.230 |
Why?
|
| Antioxidants | 2 | 2013 | 507 | 0.230 |
Why?
|
| Advance Directives | 2 | 2015 | 88 | 0.230 |
Why?
|
| Proportional Hazards Models | 6 | 2018 | 4988 | 0.230 |
Why?
|
| Child, Preschool | 13 | 2021 | 16273 | 0.230 |
Why?
|
| Psychological Tests | 1 | 2024 | 131 | 0.230 |
Why?
|
| Vena Cava, Superior | 1 | 2023 | 78 | 0.230 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2006 | 713 | 0.220 |
Why?
|
| Alanine Transaminase | 2 | 2021 | 227 | 0.220 |
Why?
|
| Health Personnel | 4 | 2020 | 625 | 0.220 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 203 | 0.220 |
Why?
|
| Fluid Therapy | 2 | 2015 | 182 | 0.220 |
Why?
|
| Computers | 1 | 2023 | 141 | 0.220 |
Why?
|
| Predictive Value of Tests | 8 | 2014 | 4892 | 0.220 |
Why?
|
| Hydrazines | 2 | 2021 | 208 | 0.220 |
Why?
|
| Attitude to Health | 3 | 2017 | 465 | 0.220 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 1823 | 0.220 |
Why?
|
| Cannabinoids | 1 | 2023 | 38 | 0.220 |
Why?
|
| Patient Admission | 3 | 2014 | 220 | 0.220 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 2013 | 94 | 0.220 |
Why?
|
| Animals | 17 | 2021 | 59536 | 0.220 |
Why?
|
| Nursing Assessment | 2 | 2013 | 42 | 0.220 |
Why?
|
| Cerebral Infarction | 1 | 2002 | 59 | 0.220 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2330 | 0.220 |
Why?
|
| Religion | 2 | 2014 | 91 | 0.210 |
Why?
|
| Fatal Outcome | 2 | 2015 | 829 | 0.210 |
Why?
|
| Dibenzothiepins | 1 | 2022 | 6 | 0.210 |
Why?
|
| International Cooperation | 2 | 2021 | 323 | 0.210 |
Why?
|
| Survival | 2 | 2014 | 177 | 0.210 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 650 | 0.210 |
Why?
|
| Air Microbiology | 2 | 2012 | 30 | 0.210 |
Why?
|
| Drug Combinations | 2 | 2021 | 621 | 0.210 |
Why?
|
| Muscarinic Antagonists | 2 | 2024 | 83 | 0.210 |
Why?
|
| Sickness Impact Profile | 2 | 2013 | 139 | 0.210 |
Why?
|
| ATP-Binding Cassette Transporters | 4 | 2011 | 299 | 0.200 |
Why?
|
| Australasia | 1 | 2021 | 5 | 0.200 |
Why?
|
| Adaptive Immunity | 1 | 2022 | 149 | 0.200 |
Why?
|
| Administration, Inhalation | 2 | 2024 | 285 | 0.200 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 1021 | 0.200 |
Why?
|
| Urine | 3 | 2020 | 143 | 0.200 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2021 | 8 | 0.200 |
Why?
|
| Civil Defense | 1 | 2021 | 13 | 0.200 |
Why?
|
| Feces | 3 | 2022 | 770 | 0.200 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2021 | 11 | 0.200 |
Why?
|
| Oxymorphone | 1 | 2021 | 9 | 0.200 |
Why?
|
| Pressure Ulcer | 1 | 2022 | 106 | 0.200 |
Why?
|
| Integrative Oncology | 1 | 2021 | 30 | 0.200 |
Why?
|
| Tobacco Use | 2 | 2018 | 54 | 0.200 |
Why?
|
| Epidemics | 2 | 2019 | 63 | 0.190 |
Why?
|
| Gastrointestinal Tract | 2 | 2021 | 324 | 0.190 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 11538 | 0.190 |
Why?
|
| Government Regulation | 1 | 2021 | 67 | 0.190 |
Why?
|
| Zoonoses | 2 | 2018 | 55 | 0.190 |
Why?
|
| Quinuclidines | 1 | 2021 | 48 | 0.190 |
Why?
|
| Herpes Zoster | 1 | 2021 | 50 | 0.190 |
Why?
|
| Water | 1 | 2022 | 361 | 0.190 |
Why?
|
| Testosterone | 4 | 2014 | 619 | 0.190 |
Why?
|
| Midazolam | 2 | 2018 | 75 | 0.190 |
Why?
|
| Isoquinolines | 1 | 2021 | 116 | 0.190 |
Why?
|
| Data Accuracy | 1 | 2020 | 54 | 0.190 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2021 | 1217 | 0.190 |
Why?
|
| Acute Lung Injury | 1 | 2021 | 92 | 0.180 |
Why?
|
| Antibodies, Neutralizing | 2 | 2023 | 541 | 0.180 |
Why?
|
| Stomach Neoplasms | 1 | 2013 | 2278 | 0.180 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 76 | 0.180 |
Why?
|
| Hydromorphone | 4 | 2023 | 58 | 0.180 |
Why?
|
| Glucocorticoids | 4 | 2010 | 629 | 0.180 |
Why?
|
| RNA, Viral | 5 | 2020 | 671 | 0.180 |
Why?
|
| Oral Sprays | 1 | 2019 | 8 | 0.180 |
Why?
|
| Hepatitis B, Chronic | 1 | 2021 | 137 | 0.180 |
Why?
|
| Alanine | 1 | 2020 | 240 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 4367 | 0.180 |
Why?
|
| Lymph Nodes | 1 | 2010 | 2967 | 0.180 |
Why?
|
| Water-Electrolyte Balance | 1 | 2019 | 104 | 0.180 |
Why?
|
| Saliva | 1 | 2020 | 231 | 0.180 |
Why?
|
| Propensity Score | 1 | 2022 | 750 | 0.170 |
Why?
|
| Escherichia coli Proteins | 1 | 2002 | 359 | 0.170 |
Why?
|
| Feasibility Studies | 2 | 2016 | 2292 | 0.170 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2018 | 1 | 0.170 |
Why?
|
| Influenza Vaccines | 2 | 2023 | 635 | 0.170 |
Why?
|
| Air Movements | 2 | 2010 | 7 | 0.170 |
Why?
|
| Oxidative Stress | 1 | 2005 | 1129 | 0.170 |
Why?
|
| Metabolome | 1 | 2022 | 344 | 0.170 |
Why?
|
| Ribavirin | 3 | 2020 | 178 | 0.170 |
Why?
|
| Intestinal Obstruction | 1 | 2021 | 202 | 0.170 |
Why?
|
| Risk Assessment | 7 | 2021 | 6869 | 0.170 |
Why?
|
| Hypogonadism | 2 | 2014 | 257 | 0.170 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 104 | 0.170 |
Why?
|
| Nutritional Support | 2 | 2017 | 80 | 0.170 |
Why?
|
| Hypoalphalipoproteinemias | 1 | 2018 | 2 | 0.170 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2018 | 13 | 0.170 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2018 | 9 | 0.170 |
Why?
|
| Immunity | 1 | 2021 | 342 | 0.160 |
Why?
|
| Saudi Arabia | 1 | 2018 | 39 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2020 | 305 | 0.160 |
Why?
|
| Interferons | 2 | 2024 | 291 | 0.160 |
Why?
|
| Patient Participation | 2 | 2023 | 446 | 0.160 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2014 | 247 | 0.160 |
Why?
|
| Acids, Carbocyclic | 2 | 2015 | 3 | 0.160 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 566 | 0.160 |
Why?
|
| Heart Rate | 2 | 2015 | 737 | 0.160 |
Why?
|
| Manikins | 1 | 2019 | 137 | 0.160 |
Why?
|
| Deep Sedation | 1 | 2018 | 21 | 0.160 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2021 | 534 | 0.160 |
Why?
|
| Administration, Buccal | 1 | 2017 | 5 | 0.160 |
Why?
|
| Vaccination | 2 | 2022 | 1123 | 0.160 |
Why?
|
| Middle East | 2 | 2015 | 46 | 0.160 |
Why?
|
| Air Pollution, Indoor | 2 | 2009 | 39 | 0.160 |
Why?
|
| Area Under Curve | 1 | 2019 | 700 | 0.150 |
Why?
|
| CD55 Antigens | 1 | 2017 | 17 | 0.150 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2017 | 23 | 0.150 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 213 | 0.150 |
Why?
|
| Meteorological Concepts | 2 | 2019 | 4 | 0.150 |
Why?
|
| Immunotherapy | 3 | 2022 | 3341 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2022 | 6207 | 0.150 |
Why?
|
| Chemokines | 2 | 2011 | 314 | 0.150 |
Why?
|
| Narcotic Antagonists | 1 | 2018 | 129 | 0.150 |
Why?
|
| Cooperative Behavior | 2 | 2018 | 313 | 0.150 |
Why?
|
| Virus Shedding | 3 | 2020 | 88 | 0.150 |
Why?
|
| Triazoles | 1 | 2021 | 617 | 0.150 |
Why?
|
| Consciousness | 1 | 2017 | 56 | 0.150 |
Why?
|
| Hypodermoclysis | 1 | 2016 | 4 | 0.150 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 244 | 0.150 |
Why?
|
| Microbiota | 1 | 2023 | 547 | 0.150 |
Why?
|
| Risperidone | 1 | 2017 | 62 | 0.150 |
Why?
|
| Nasal Sprays | 1 | 2016 | 7 | 0.150 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 341 | 0.140 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 90 | 0.140 |
Why?
|
| Infant | 7 | 2021 | 13310 | 0.140 |
Why?
|
| Politics | 2 | 2020 | 74 | 0.140 |
Why?
|
| Sex Factors | 3 | 2016 | 2139 | 0.140 |
Why?
|
| Propofol | 1 | 2017 | 80 | 0.140 |
Why?
|
| Informed Consent | 1 | 2020 | 419 | 0.140 |
Why?
|
| Physical Stimulation | 2 | 2006 | 112 | 0.140 |
Why?
|
| Prednisolone | 3 | 2005 | 123 | 0.140 |
Why?
|
| Food Packaging | 1 | 2015 | 1 | 0.140 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 1225 | 0.140 |
Why?
|
| Steam | 1 | 2015 | 6 | 0.140 |
Why?
|
| Plasma | 1 | 2017 | 158 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 1033 | 0.140 |
Why?
|
| Physician's Role | 1 | 2018 | 238 | 0.140 |
Why?
|
| Chemical Phenomena | 1 | 2015 | 137 | 0.140 |
Why?
|
| Drug Discovery | 2 | 2020 | 324 | 0.140 |
Why?
|
| Aging | 3 | 2018 | 1582 | 0.140 |
Why?
|
| Bacterial Proteins | 1 | 2002 | 1029 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 292 | 0.140 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2015 | 35 | 0.140 |
Why?
|
| Polyesters | 1 | 2015 | 53 | 0.140 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2016 | 48 | 0.140 |
Why?
|
| Hydrocortisone | 3 | 2014 | 388 | 0.140 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2015 | 30 | 0.140 |
Why?
|
| Bereavement | 1 | 2015 | 27 | 0.140 |
Why?
|
| Health Behavior | 1 | 2020 | 603 | 0.130 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2015 | 85 | 0.130 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2015 | 93 | 0.130 |
Why?
|
| Influenza A Virus, H10N8 Subtype | 1 | 2015 | 1 | 0.130 |
Why?
|
| Organizational Innovation | 1 | 2015 | 68 | 0.130 |
Why?
|
| Surface Properties | 1 | 2015 | 180 | 0.130 |
Why?
|
| Child | 14 | 2021 | 29154 | 0.130 |
Why?
|
| Urban Population | 1 | 2016 | 269 | 0.130 |
Why?
|
| Immunity, Innate | 2 | 2024 | 677 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 383 | 0.130 |
Why?
|
| RNA-Binding Proteins | 2 | 2021 | 984 | 0.130 |
Why?
|
| Autonomic Nervous System | 1 | 2015 | 72 | 0.130 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2015 | 94 | 0.130 |
Why?
|
| Beijing | 1 | 2015 | 13 | 0.130 |
Why?
|
| Odds Ratio | 3 | 2022 | 2316 | 0.130 |
Why?
|
| Zanamivir | 1 | 2015 | 8 | 0.130 |
Why?
|
| Video Recording | 2 | 2007 | 267 | 0.130 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2015 | 90 | 0.130 |
Why?
|
| Regression Analysis | 2 | 2015 | 1546 | 0.130 |
Why?
|
| Probability | 3 | 2014 | 866 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 3 | 2011 | 3203 | 0.130 |
Why?
|
| Canada | 2 | 2021 | 429 | 0.130 |
Why?
|
| Carbon | 1 | 2015 | 149 | 0.130 |
Why?
|
| Physical Endurance | 2 | 2005 | 58 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2021 | 3639 | 0.130 |
Why?
|
| Amino Acid Sequence | 6 | 2005 | 4233 | 0.130 |
Why?
|
| Hot Temperature | 1 | 2015 | 281 | 0.130 |
Why?
|
| Vocal Cords | 1 | 2015 | 90 | 0.130 |
Why?
|
| Radiography, Thoracic | 4 | 2004 | 462 | 0.130 |
Why?
|
| Protective Factors | 1 | 2015 | 106 | 0.130 |
Why?
|
| Medicine | 1 | 2016 | 137 | 0.130 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2014 | 8 | 0.120 |
Why?
|
| Refuse Disposal | 1 | 2014 | 10 | 0.120 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2014 | 8 | 0.120 |
Why?
|
| Family Relations | 1 | 2015 | 88 | 0.120 |
Why?
|
| Linear Models | 2 | 2014 | 1085 | 0.120 |
Why?
|
| Influenza B virus | 2 | 2012 | 127 | 0.120 |
Why?
|
| Atropine | 1 | 2014 | 52 | 0.120 |
Why?
|
| Mouth | 1 | 2015 | 122 | 0.120 |
Why?
|
| Drug Storage | 1 | 2014 | 29 | 0.120 |
Why?
|
| Erythrocytes | 1 | 2015 | 339 | 0.120 |
Why?
|
| Frail Elderly | 1 | 2015 | 118 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2015 | 445 | 0.120 |
Why?
|
| Eyelids | 1 | 2015 | 163 | 0.120 |
Why?
|
| Disease Management | 1 | 2020 | 1052 | 0.120 |
Why?
|
| Biological Therapy | 1 | 2014 | 58 | 0.120 |
Why?
|
| Smoking | 2 | 2015 | 2440 | 0.120 |
Why?
|
| Communication Barriers | 1 | 2014 | 52 | 0.120 |
Why?
|
| Interleukin-1alpha | 1 | 2014 | 56 | 0.120 |
Why?
|
| Demography | 1 | 2015 | 435 | 0.120 |
Why?
|
| Diet, High-Fat | 1 | 2015 | 241 | 0.120 |
Why?
|
| Subcutaneous Absorption | 1 | 2013 | 4 | 0.120 |
Why?
|
| Social Perception | 1 | 2014 | 76 | 0.120 |
Why?
|
| Pyridines | 1 | 2021 | 1244 | 0.120 |
Why?
|
| Molecular Sequence Data | 6 | 2005 | 6089 | 0.120 |
Why?
|
| Respiratory Rate | 1 | 2013 | 11 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2002 | 2022 | 0.120 |
Why?
|
| Protein Transport | 2 | 2018 | 734 | 0.120 |
Why?
|
| Placebo Effect | 1 | 2013 | 39 | 0.120 |
Why?
|
| Pulmonary Emphysema | 2 | 2006 | 145 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2014 | 205 | 0.120 |
Why?
|
| Mycophenolic Acid | 1 | 2014 | 148 | 0.120 |
Why?
|
| Injections, Spinal | 2 | 2012 | 257 | 0.120 |
Why?
|
| Pain, Intractable | 2 | 2012 | 171 | 0.120 |
Why?
|
| Infant, Newborn | 2 | 2017 | 8223 | 0.110 |
Why?
|
| Rest | 1 | 2013 | 71 | 0.110 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 735 | 0.110 |
Why?
|
| Body Image | 1 | 2014 | 141 | 0.110 |
Why?
|
| Indans | 1 | 2013 | 68 | 0.110 |
Why?
|
| Vitamin D | 2 | 2014 | 261 | 0.110 |
Why?
|
| Acetaminophen | 1 | 2014 | 116 | 0.110 |
Why?
|
| Phenotype | 2 | 2022 | 6295 | 0.110 |
Why?
|
| Perception | 1 | 2015 | 350 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2015 | 417 | 0.110 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2012 | 25 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 1085 | 0.110 |
Why?
|
| Radiography | 3 | 2014 | 1904 | 0.110 |
Why?
|
| Inflammation | 4 | 2021 | 2522 | 0.110 |
Why?
|
| Melatonin | 1 | 2013 | 46 | 0.110 |
Why?
|
| Alcohol Drinking | 2 | 2015 | 551 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 8865 | 0.110 |
Why?
|
| Suicidal Ideation | 1 | 2015 | 207 | 0.110 |
Why?
|
| Cross-Cultural Comparison | 2 | 2024 | 87 | 0.110 |
Why?
|
| Review Literature as Topic | 1 | 2013 | 71 | 0.110 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2014 | 126 | 0.110 |
Why?
|
| Marriage | 1 | 2012 | 45 | 0.110 |
Why?
|
| Analysis of Variance | 3 | 2018 | 2307 | 0.110 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2015 | 211 | 0.110 |
Why?
|
| APACHE | 1 | 2012 | 93 | 0.110 |
Why?
|
| Dehydration | 1 | 2012 | 87 | 0.110 |
Why?
|
| Genes, Viral | 1 | 2012 | 202 | 0.110 |
Why?
|
| Skin Tests | 1 | 2012 | 96 | 0.110 |
Why?
|
| Quinolones | 1 | 2013 | 160 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 294 | 0.110 |
Why?
|
| Sulfur Dioxide | 1 | 2012 | 4 | 0.110 |
Why?
|
| Japan | 2 | 2023 | 227 | 0.110 |
Why?
|
| Music | 1 | 2012 | 36 | 0.110 |
Why?
|
| Ascites | 1 | 2013 | 198 | 0.110 |
Why?
|
| Nitrogen Dioxide | 1 | 2012 | 17 | 0.110 |
Why?
|
| Immunoglobulin E | 1 | 2012 | 163 | 0.100 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2012 | 84 | 0.100 |
Why?
|
| Nursing Homes | 1 | 2012 | 99 | 0.100 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 174 | 0.100 |
Why?
|
| Poisson Distribution | 1 | 2012 | 91 | 0.100 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 1323 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2014 | 597 | 0.100 |
Why?
|
| Ozone | 1 | 2012 | 33 | 0.100 |
Why?
|
| Sleep Deprivation | 1 | 2012 | 51 | 0.100 |
Why?
|
| Medical Staff, Hospital | 1 | 2012 | 118 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 1054 | 0.100 |
Why?
|
| Body Height | 1 | 2012 | 231 | 0.100 |
Why?
|
| Particle Size | 1 | 2012 | 182 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2019 | 806 | 0.100 |
Why?
|
| Public Health | 1 | 2014 | 299 | 0.100 |
Why?
|
| Saposins | 1 | 2011 | 1 | 0.100 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2011 | 5 | 0.100 |
Why?
|
| Combinatorial Chemistry Techniques | 2 | 2002 | 37 | 0.100 |
Why?
|
| Cathepsin D | 1 | 2011 | 32 | 0.100 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2011 | 17 | 0.100 |
Why?
|
| Fibroblasts | 1 | 2018 | 1682 | 0.100 |
Why?
|
| Constipation | 1 | 2012 | 177 | 0.100 |
Why?
|
| Parenteral Nutrition | 1 | 2012 | 207 | 0.100 |
Why?
|
| Particulate Matter | 1 | 2012 | 86 | 0.100 |
Why?
|
| Emotions | 1 | 2015 | 562 | 0.100 |
Why?
|
| Critical Illness | 2 | 2014 | 714 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 622 | 0.100 |
Why?
|
| Child Abuse, Sexual | 1 | 2011 | 34 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2014 | 901 | 0.090 |
Why?
|
| Gram-Negative Bacteria | 1 | 2011 | 100 | 0.090 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2015 | 342 | 0.090 |
Why?
|
| Lipase | 1 | 2011 | 112 | 0.090 |
Why?
|
| Disasters | 1 | 2012 | 107 | 0.090 |
Why?
|
| Reference Values | 1 | 2012 | 1099 | 0.090 |
Why?
|
| Hospitals, Public | 1 | 2010 | 64 | 0.090 |
Why?
|
| Catheters | 1 | 2011 | 126 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 115 | 0.090 |
Why?
|
| Activities of Daily Living | 3 | 2023 | 552 | 0.090 |
Why?
|
| Abdominal Pain | 1 | 2013 | 369 | 0.090 |
Why?
|
| Respiratory Muscles | 1 | 2010 | 27 | 0.090 |
Why?
|
| Recovery of Function | 2 | 2023 | 703 | 0.090 |
Why?
|
| Muscle, Skeletal | 3 | 2012 | 1270 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 589 | 0.090 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2013 | 565 | 0.090 |
Why?
|
| Quality Control | 1 | 2011 | 457 | 0.090 |
Why?
|
| Network Meta-Analysis | 2 | 2022 | 31 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2008 | 10331 | 0.090 |
Why?
|
| Depressive Disorder | 1 | 2014 | 557 | 0.090 |
Why?
|
| Quarantine | 1 | 2009 | 20 | 0.090 |
Why?
|
| Gastrectomy | 1 | 2013 | 451 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 598 | 0.090 |
Why?
|
| Leukemia | 1 | 2018 | 1635 | 0.090 |
Why?
|
| Aminopyridines | 1 | 2011 | 212 | 0.090 |
Why?
|
| Anaerobic Threshold | 1 | 2009 | 11 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2018 | 2086 | 0.090 |
Why?
|
| Mice, Knockout | 4 | 2015 | 5710 | 0.090 |
Why?
|
| Patient Care Management | 1 | 2010 | 94 | 0.090 |
Why?
|
| Adipose Tissue | 2 | 2012 | 769 | 0.090 |
Why?
|
| Muscle Strength | 1 | 2010 | 104 | 0.090 |
Why?
|
| Analgesia | 1 | 2010 | 94 | 0.090 |
Why?
|
| Status Asthmaticus | 1 | 2009 | 21 | 0.090 |
Why?
|
| Air | 1 | 2009 | 63 | 0.090 |
Why?
|
| Affective Symptoms | 1 | 2010 | 102 | 0.090 |
Why?
|
| Garcinia | 1 | 2008 | 1 | 0.090 |
Why?
|
| Fasting | 1 | 2011 | 349 | 0.080 |
Why?
|
| Biflavonoids | 1 | 2008 | 4 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2011 | 365 | 0.080 |
Why?
|
| Placebos | 1 | 2010 | 437 | 0.080 |
Why?
|
| Mental Recall | 1 | 2010 | 171 | 0.080 |
Why?
|
| Trachea | 1 | 2011 | 259 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 672 | 0.080 |
Why?
|
| Long QT Syndrome | 1 | 2010 | 92 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2010 | 875 | 0.080 |
Why?
|
| Administration, Cutaneous | 1 | 2009 | 141 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2010 | 430 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2014 | 834 | 0.080 |
Why?
|
| Health Surveys | 1 | 2010 | 402 | 0.080 |
Why?
|
| British Columbia | 1 | 2008 | 24 | 0.080 |
Why?
|
| Travel | 1 | 2009 | 190 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2008 | 129 | 0.080 |
Why?
|
| Tunica Intima | 1 | 2008 | 117 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 15862 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 3976 | 0.080 |
Why?
|
| Neopterin | 1 | 2007 | 13 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2005 | 1271 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 864 | 0.080 |
Why?
|
| Drug Evaluation | 1 | 2008 | 425 | 0.080 |
Why?
|
| Prednisone | 1 | 2010 | 984 | 0.080 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2008 | 222 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2012 | 492 | 0.080 |
Why?
|
| Alemtuzumab | 1 | 2008 | 198 | 0.080 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2009 | 118 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2017 | 2819 | 0.080 |
Why?
|
| Atherosclerosis | 1 | 2015 | 935 | 0.080 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2008 | 198 | 0.080 |
Why?
|
| Viral Vaccines | 1 | 2009 | 304 | 0.070 |
Why?
|
| Snoring | 1 | 2006 | 13 | 0.070 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2006 | 47 | 0.070 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2006 | 38 | 0.070 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2008 | 330 | 0.070 |
Why?
|
| Calcitonin | 1 | 2007 | 186 | 0.070 |
Why?
|
| Chemoradiotherapy | 2 | 2013 | 1946 | 0.070 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2006 | 47 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2010 | 649 | 0.070 |
Why?
|
| United Kingdom | 2 | 2022 | 257 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 4744 | 0.070 |
Why?
|
| Nurses | 2 | 2019 | 80 | 0.070 |
Why?
|
| Psychotherapy, Group | 1 | 2006 | 59 | 0.070 |
Why?
|
| Vincristine | 1 | 2010 | 1511 | 0.070 |
Why?
|
| Occupational Health | 1 | 2006 | 95 | 0.070 |
Why?
|
| Accidents, Traffic | 1 | 2006 | 116 | 0.070 |
Why?
|
| Benzamides | 1 | 2011 | 1832 | 0.070 |
Why?
|
| Protein Precursors | 1 | 2007 | 240 | 0.070 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2006 | 173 | 0.070 |
Why?
|
| Chemokine CXCL1 | 1 | 2005 | 60 | 0.070 |
Why?
|
| Neutropenia | 2 | 2008 | 968 | 0.070 |
Why?
|
| Equipment Failure | 1 | 2006 | 191 | 0.070 |
Why?
|
| Copper Sulfate | 1 | 2005 | 4 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 1489 | 0.070 |
Why?
|
| Apolipoprotein E3 | 1 | 2005 | 16 | 0.070 |
Why?
|
| Equipment Design | 1 | 2009 | 1204 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 698 | 0.070 |
Why?
|
| Respiratory Sounds | 1 | 2006 | 95 | 0.070 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 1178 | 0.070 |
Why?
|
| Rituximab | 1 | 2010 | 1528 | 0.060 |
Why?
|
| Tubulin | 1 | 2005 | 169 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2008 | 366 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2008 | 348 | 0.060 |
Why?
|
| Thrombocytopenia | 2 | 2008 | 846 | 0.060 |
Why?
|
| Lipoproteins, LDL | 1 | 2005 | 163 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 157 | 0.060 |
Why?
|
| Mycosis Fungoides | 1 | 2008 | 320 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2004 | 7551 | 0.060 |
Why?
|
| Task Performance and Analysis | 1 | 2005 | 136 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2008 | 627 | 0.060 |
Why?
|
| Occupational Diseases | 1 | 2005 | 130 | 0.060 |
Why?
|
| Personnel, Hospital | 1 | 2004 | 40 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2019 | 5542 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 666 | 0.060 |
Why?
|
| Oxycodone | 1 | 2023 | 29 | 0.060 |
Why?
|
| Taiwan | 1 | 2023 | 93 | 0.060 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2009 | 581 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2011 | 1664 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2010 | 3001 | 0.060 |
Why?
|
| Hydroxylamines | 1 | 2022 | 8 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2010 | 3005 | 0.060 |
Why?
|
| Levorphanol | 1 | 2023 | 14 | 0.060 |
Why?
|
| Lysine | 1 | 2005 | 422 | 0.060 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 9 | 0.060 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2005 | 362 | 0.060 |
Why?
|
| Thyrotropin | 2 | 2014 | 119 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2005 | 842 | 0.050 |
Why?
|
| Medical Records | 2 | 2015 | 415 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 5112 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2010 | 573 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2005 | 487 | 0.050 |
Why?
|
| Amino Acid Motifs | 2 | 2000 | 392 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2012 | 10035 | 0.050 |
Why?
|
| Pneumococcal Infections | 1 | 2004 | 241 | 0.050 |
Why?
|
| Pleural Effusion | 1 | 2004 | 201 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 2015 | 497 | 0.050 |
Why?
|
| Oncogenes | 1 | 2005 | 673 | 0.050 |
Why?
|
| Germany | 1 | 2022 | 111 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 543 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2002 | 209 | 0.050 |
Why?
|
| Hemolysis | 1 | 2002 | 127 | 0.050 |
Why?
|
| Arginine | 1 | 2005 | 500 | 0.050 |
Why?
|
| Hematologic Diseases | 1 | 2003 | 242 | 0.050 |
Why?
|
| Hemoglobins | 3 | 2014 | 477 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2018 | 1544 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 1487 | 0.050 |
Why?
|
| Metoclopramide | 1 | 2021 | 33 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 3472 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 6915 | 0.050 |
Why?
|
| Transferases | 1 | 2021 | 9 | 0.050 |
Why?
|
| Gene Library | 1 | 2002 | 294 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 490 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2021 | 84 | 0.050 |
Why?
|
| Mediastinal Neoplasms | 1 | 2005 | 423 | 0.050 |
Why?
|
| Nose | 1 | 2023 | 192 | 0.050 |
Why?
|
| Triazines | 1 | 2022 | 117 | 0.050 |
Why?
|
| Tertiary Healthcare | 1 | 2021 | 44 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2021 | 43 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2002 | 611 | 0.050 |
Why?
|
| Harm Reduction | 1 | 2020 | 16 | 0.050 |
Why?
|
| Bronchoscopy | 1 | 2004 | 474 | 0.050 |
Why?
|
| Fever | 2 | 2020 | 497 | 0.050 |
Why?
|
| Protein Binding | 2 | 2005 | 3438 | 0.050 |
Why?
|
| Lopinavir | 1 | 2020 | 12 | 0.050 |
Why?
|
| Vero Cells | 1 | 2021 | 143 | 0.050 |
Why?
|
| Biological Transport | 1 | 2002 | 597 | 0.050 |
Why?
|
| Pleural Neoplasms | 1 | 2005 | 470 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2021 | 173 | 0.050 |
Why?
|
| Authoritarianism | 1 | 2020 | 10 | 0.050 |
Why?
|
| Malaysia | 1 | 2020 | 20 | 0.050 |
Why?
|
| Cognition | 1 | 2006 | 968 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2021 | 299 | 0.050 |
Why?
|
| Liver Function Tests | 1 | 2020 | 173 | 0.050 |
Why?
|
| Morpholines | 1 | 2022 | 289 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2011 | 4078 | 0.050 |
Why?
|
| Hope | 1 | 2020 | 13 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2021 | 2084 | 0.050 |
Why?
|
| Hospital Units | 2 | 2010 | 38 | 0.050 |
Why?
|
| Mesothelioma | 1 | 2005 | 544 | 0.050 |
Why?
|
| Cultural Characteristics | 1 | 2019 | 70 | 0.040 |
Why?
|
| Humidity | 1 | 2019 | 29 | 0.040 |
Why?
|
| Anti-Infective Agents | 2 | 2014 | 446 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2020 | 383 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 2927 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2021 | 180 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 2021 | 217 | 0.040 |
Why?
|
| Pyridones | 1 | 2022 | 348 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2000 | 261 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 140 | 0.040 |
Why?
|
| Mice | 5 | 2015 | 34495 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2020 | 172 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2023 | 657 | 0.040 |
Why?
|
| World Health Organization | 1 | 2020 | 316 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2021 | 429 | 0.040 |
Why?
|
| Base Sequence | 3 | 2000 | 4917 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2002 | 875 | 0.040 |
Why?
|
| Airway Management | 1 | 2020 | 102 | 0.040 |
Why?
|
| Pneumonectomy | 1 | 2004 | 831 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 558 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 299 | 0.040 |
Why?
|
| Counseling | 1 | 2021 | 381 | 0.040 |
Why?
|
| Algorithms | 1 | 2010 | 3890 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2004 | 299 | 0.040 |
Why?
|
| Apolipoprotein A-I | 1 | 2018 | 84 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2005 | 821 | 0.040 |
Why?
|
| Bacteremia | 1 | 2004 | 689 | 0.040 |
Why?
|
| Curriculum | 1 | 2023 | 860 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2000 | 571 | 0.040 |
Why?
|
| Temperature | 1 | 2019 | 506 | 0.040 |
Why?
|
| Cholesterol | 1 | 2021 | 658 | 0.040 |
Why?
|
| Stents | 1 | 2004 | 1096 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 7548 | 0.040 |
Why?
|
| Behavior, Addictive | 1 | 2018 | 99 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2020 | 1053 | 0.040 |
Why?
|
| Respiration, Artificial | 2 | 2015 | 577 | 0.040 |
Why?
|
| Appetite Stimulants | 1 | 2017 | 14 | 0.040 |
Why?
|
| Protein Stability | 1 | 2018 | 370 | 0.040 |
Why?
|
| Electrocardiography | 2 | 2015 | 1145 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 666 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2017 | 166 | 0.040 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2016 | 42 | 0.040 |
Why?
|
| Clonidine | 1 | 2016 | 71 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2000 | 1258 | 0.040 |
Why?
|
| Salmeterol Xinafoate | 1 | 2016 | 22 | 0.040 |
Why?
|
| Safety-net Providers | 1 | 2016 | 53 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 3251 | 0.040 |
Why?
|
| Chronic Pain | 1 | 2020 | 238 | 0.040 |
Why?
|
| Fluticasone | 1 | 2016 | 23 | 0.040 |
Why?
|
| Amines | 1 | 2016 | 85 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 1382 | 0.040 |
Why?
|
| Hypoxia | 1 | 2019 | 443 | 0.030 |
Why?
|
| RNA | 1 | 2021 | 1013 | 0.030 |
Why?
|
| Marital Status | 1 | 2015 | 98 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 15694 | 0.030 |
Why?
|
| Triglycerides | 1 | 2018 | 603 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 2390 | 0.030 |
Why?
|
| Phylogeny | 2 | 2012 | 826 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2016 | 269 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2014 | 60 | 0.030 |
Why?
|
| Autophagy | 1 | 2021 | 927 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2015 | 260 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 5767 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2015 | 229 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 1163 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 5539 | 0.030 |
Why?
|
| Energy Intake | 1 | 2017 | 515 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 2014 | 73 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1998 | 852 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 1489 | 0.030 |
Why?
|
| Tiotropium Bromide | 1 | 2013 | 22 | 0.030 |
Why?
|
| Scopolamine Derivatives | 1 | 2013 | 15 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 397 | 0.030 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2013 | 16 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2014 | 140 | 0.030 |
Why?
|
| Hydrocodone | 1 | 2014 | 55 | 0.030 |
Why?
|
| Mitochondria | 1 | 2000 | 1282 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 1258 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 671 | 0.030 |
Why?
|
| Alcohol Withdrawal Seizures | 1 | 2012 | 4 | 0.030 |
Why?
|
| Developing Countries | 1 | 2015 | 315 | 0.030 |
Why?
|
| Self Concept | 1 | 2014 | 211 | 0.030 |
Why?
|
| DNA | 1 | 2021 | 2693 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 6942 | 0.030 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2012 | 33 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 3578 | 0.030 |
Why?
|
| Causality | 1 | 2012 | 178 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 289 | 0.030 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2012 | 73 | 0.030 |
Why?
|
| Pyriform Sinus | 1 | 2011 | 8 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2012 | 249 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2011 | 77 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 14551 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2011 | 88 | 0.030 |
Why?
|
| Paclitaxel | 1 | 1998 | 1996 | 0.020 |
Why?
|
| Anthropometry | 1 | 2012 | 269 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2003 | 2341 | 0.020 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2011 | 133 | 0.020 |
Why?
|
| Medical Audit | 1 | 2011 | 188 | 0.020 |
Why?
|
| Androgens | 1 | 2014 | 511 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2014 | 1290 | 0.020 |
Why?
|
| Hemagglutinins, Viral | 1 | 2010 | 45 | 0.020 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 308 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 289 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 591 | 0.020 |
Why?
|
| Data Collection | 1 | 2012 | 620 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2012 | 994 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2011 | 205 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2010 | 201 | 0.020 |
Why?
|
| Macrophages | 1 | 2015 | 1304 | 0.020 |
Why?
|
| Pseudopodia | 1 | 2008 | 30 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2009 | 96 | 0.020 |
Why?
|
| Alberta | 1 | 2008 | 65 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2008 | 138 | 0.020 |
Why?
|
| Methadone | 1 | 2010 | 195 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 1293 | 0.020 |
Why?
|
| Apoptosis | 2 | 2015 | 7591 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2008 | 557 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 2008 | 176 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2011 | 6150 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2013 | 1085 | 0.020 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2007 | 163 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2011 | 674 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2006 | 354 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 2074 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2005 | 105 | 0.020 |
Why?
|
| Asbestos | 1 | 2005 | 35 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 4549 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2010 | 1529 | 0.020 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2004 | 36 | 0.020 |
Why?
|
| Convalescence | 1 | 2004 | 25 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 2483 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2004 | 41 | 0.020 |
Why?
|
| Fuzzy Logic | 1 | 2004 | 8 | 0.020 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2004 | 34 | 0.020 |
Why?
|
| Tuberculosis, Pleural | 1 | 2004 | 11 | 0.020 |
Why?
|
| Chills | 1 | 2003 | 16 | 0.010 |
Why?
|
| Recurrence | 1 | 2012 | 4758 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 2005 | 244 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 2011 | 1202 | 0.010 |
Why?
|
| Autopsy | 1 | 2003 | 173 | 0.010 |
Why?
|
| Contact Tracing | 1 | 2003 | 56 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2015 | 7226 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2003 | 193 | 0.010 |
Why?
|
| Platelet Count | 1 | 2003 | 490 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 2003 | 185 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 2003 | 170 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 486 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2004 | 467 | 0.010 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2004 | 500 | 0.010 |
Why?
|
| Lymphopenia | 1 | 2003 | 199 | 0.010 |
Why?
|
| Physical Chromosome Mapping | 1 | 2000 | 73 | 0.010 |
Why?
|
| Rats | 2 | 2000 | 6086 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2000 | 108 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 2283 | 0.010 |
Why?
|
| Pseudogenes | 1 | 2000 | 81 | 0.010 |
Why?
|
| Registries | 1 | 2008 | 2170 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 5637 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 8873 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2000 | 231 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2000 | 327 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 997 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2000 | 844 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 4109 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 1213 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1998 | 172 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 1399 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1998 | 587 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2003 | 3842 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 3981 | 0.010 |
Why?
|
| Transfection | 1 | 2000 | 2944 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 5437 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 2232 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 1471 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 4053 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2000 | 2358 | 0.010 |
Why?
|
| Cell Line | 1 | 2000 | 5114 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2000 | 5159 | 0.000 |
Why?
|
| Mutation | 1 | 2006 | 15179 | 0.000 |
Why?
|